¼¼°èÀÇ ³ë·Î¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå
Norovirus Diagnostics
»óǰÄÚµå : 1795284
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 132 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

³ë·Î¹ÙÀÌ·¯½º Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 610¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 6,900¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ³ë·Î¹ÙÀÌ·¯½º Áø´Ü ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 7.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 610¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½Å¼Ó °Ë»ç ŰƮ´Â CAGR 7.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 6,830¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. PCR ŰƮ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1,810¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ³ë·Î¹ÙÀÌ·¯½º Áø´Ü ½ÃÀåÀº 2024³â¿¡´Â 1,810¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 7.2%·Î 2030³â±îÁö 1,700¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 6.9%¿Í 6.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ³ë·Î¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÇ·á ÇöÀå¿¡¼­ ³ë·Î¹ÙÀÌ·¯½º °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

³ë·Î¹ÙÀÌ·¯½º´Â Àü ¼¼°èÀûÀ¸·Î °¡Àå ÈçÇÑ ¹ÙÀÌ·¯½º¼º À§Àå¿°ÀÇ ¿øÀÎ Áß ÇϳªÀ̸ç, ¸ðµç ¿¬·É´ëÀÇ »ç¶÷µéÀÌ °¨¿°µÇ°í ÀÖ½À´Ï´Ù. Àü¿°¼ºÀÌ ³ô±â ¶§¹®¿¡ º´¿ø, Àå±â¿ä¾ç½Ã¼³, Çб³, À¯¶÷¼± µî¿¡¼­ Áý´Ü °¨¿°ÀÌ ÀÚÁÖ ¹ß»ýÇÕ´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ °¨¿° È®»êÀ» ¾ïÁ¦Çϰí Áý´Ü °¨¿°À» È¿À²ÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ Àû½Ã¿¡ Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ´Ù¸¥ À§À庴°ú ´Þ¸® ³ë·Î¹ÙÀÌ·¯½º´Â ¿À¿°µÈ Ç¥¸é, À½½Ä, ¹°À» ÅëÇØ ºü¸£°Ô ÀüÆÄµÇ±â ¶§¹®¿¡ Á¶±â¿¡ ¹ß°ßÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù.

ÇöÀç ³ë·Î¹ÙÀÌ·¯½º °Ë»ç´Â ƯÈ÷ ½Ã¼³ ȯ°æ¿¡¼­ ±Þ¼º ¼³»ç¸¦ º¸À̴ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÀÏ»óÀûÀÎ Áø´Ü¿¡ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÓ»óÀǵéÀº ³ë·Î¹ÙÀÌ·¯½º¸¦ ¼¼±ÕÀ̳ª ´Ù¸¥ ¹ÙÀÌ·¯½º °¨¿°°ú ±¸º°ÇÒ ¼ö ÀÖ´Â ½Å¼ÓÇÏ°í ¹Î°¨ÇÑ µµ±¸°¡ Á¡Á¡ ´õ ¸¹ÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¿Ü·¡ Áø·á ¹× ÀÀ±Þ ÇöÀå¿¡¼­ÀÇ Áø´Ü °Ë»ç äÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ÀÓ»óÀû ÀνÄÀÇ Áõ°¡¿Í °¨¿° °ü¸® ÇÁ·ÎÅäÄÝ¿¡ ´ëÇÑ ±ÔÁ¦°¡ °­È­µÇ°í ÀÖÀ½À» ¹Ý¿µÇÕ´Ï´Ù.

¼Óµµ¿Í Á¤È®¼ºÀ» Çâ»ó½ÃŰ´Â Áø´Ü ±â¼úÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀ¸·Î ±âÁ¸ÀÇ È¿¼Ò ¸é¿ª ÃøÁ¤¹ý¿¡¼­ º¸´Ù ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Á¦°øÇÏ´Â ºÐÀÚÁø´Ü¹ýÀ¸·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù. ´ëº¯ °Ëü¿¡¼­ ³ë·Î¹ÙÀÌ·¯½º À¯ÀüÀÚ±ºÀ» °ËÃâÇϱâ À§ÇØ ÇöÀç ½Ç½Ã°£ PCR ±â¹Ý ºÐ¼®¹ýÀ̳ª ¸ÖƼÇ÷º½º ÆÐ³ÎÀÌ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ºü¸¥ °á°ú¸¦ Á¦°øÇϱ⠶§¹®¿¡ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ Àû½Ã¿¡ ¿¹¹æ Á¶Ä¡¸¦ ÃëÇϰí ÀûÀýÇÑ Ä¡·á¸¦ ½ÃÀÛÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Áø·á¼Ò³ª ¿ä¾ç½Ã¼³¿¡¼­ ºÐ»êÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Â Point-of-Care °Ë»ç Àåºñµµ µîÀåÇϰí ÀÖ¾î, Áß¾Ó ÁýÁᫎ °Ë»ç½Ç ¾øÀ̵µ ºü¸¥ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ºÐ¼® ¼³°è, »ùÇà Á¶Á¦, ÇÙ»ê ÁõÆøÀÇ °³¼±À¸·Î ³·Àº ¹ÙÀÌ·¯½º ¾çÀ» ¾ÈÁ¤ÀûÀ¸·Î °ËÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ´Ù¸¥ Àå³» º´¿øÃ¼¿Í ÇÔ²² ³ë·Î¹ÙÀÌ·¯½º¸¦ Æ÷ÇÔÇÑ ´ÙÁß ºÐÀÚ °Ë»ç´Â À§Àå¿° »ç·ÊÀÇ Áø´ÜÀ» °£¼ÒÈ­Çϱâ À§ÇØ ÀÓ»ó ¿öÅ©Ç÷ο쿡¼­ Á¡Á¡ ´õ ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

¾î¶² ½Ã¼³°ú °øÁß º¸°Ç µ¿ÇâÀÌ °Ë»ç äÅÃÀ» È®´ëÇϰí Àִ°¡?

º´¿ø, Çб³, ³ëÀοä¾ç¿ø µî ½Ã¼³µéÀº ³ë·Î¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ ¿µÇâÀ» ÁÙÀ̱â À§ÇØ ³ë·Î¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ÀÏ»óÀûÀÎ °ËÁø ÇÁ·ÎÅäÄÝ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. °øÁß º¸°Ç ±â°üÀº °íÀ§Çè ȯ°æ¿¡¼­ ±Þ¼º À§Àå¿°À» °ü¸®Çϱâ À§ÇÑ °¡À̵å¶óÀÎÀ» °­È­Çϰí, Áø´Ü °Ë»ç ºóµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. °Ë»ç½Ç¿¡¼­´Â ¼º¼ö±â³ª ¹ßº´ ½Ã ³ë·Î¹ÙÀÌ·¯½º °ËÃâÀÇ ³ôÀº 󸮷®À» °¡´ÉÇÏ°Ô ÇÏ´Â ÀÚµ¿È­ ½Ã½ºÅÛ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°è ¿©Çà¾÷°è¿Í ¿Ü½Ä¾÷°èµµ ½ÄÁßµ¶°ú ¼öÀμº °¨¿°À¸·Î ÀÎÇØ Áø´Ü °¨½Ã ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇÑ ¸òÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ½Äǰ¾ÈÀü½ÃÇè¼Ò ¹× ȯ°æ°Ë»ç ¼­ºñ½º ¾÷üµéÀº ±ÔÁ¤ Áؼö ¹× ǰÁú °ü¸® ±âÁØÀ» ÃæÁ·Çϱâ À§ÇØ ³ë·Î¹ÙÀÌ·¯½º °Ë»ç¹ýÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚÇü º¯ÀÌ ¹× ¹ß»ý¿øÀ» ÃßÀûÇÏ´Â °¨½Ã ÇÁ·Î±×·¥Àº ½ÇÇè½Ç¿¡¼­ È®ÀÎµÈ ³ë·Î¹ÙÀÌ·¯½º »ç·Ê¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖÀ¸¸ç, Áø´ÜÇÐÀº ´õ ±¤¹üÀ§ÇÑ ¿ªÇÐ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ¿¡ ÅëÇյǾî ÀÖ½À´Ï´Ù.

³ë·Î¹ÙÀÌ·¯½º Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù.

½Ã¼³ ¹× Áö¿ª»çȸ¿¡¼­ ³ë·Î¹ÙÀÌ·¯½º °ü·Ã ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½Ç½Ã°£ PCR, ¸ÖƼÇ÷º½º Ç÷§Æû µî ºÐÀÚ °Ë»ç ±â¼úÀÇ Çâ»óÀ¸·Î °ËÃâ ¼Óµµ¿Í ½Å·Ú¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. º´¿ø, Àå±â¿ä¾ç½Ã¼³, Çб³¿¡¼­ÀÇ °¨¿° °ü¸® ÇÁ·ÎÅäÄÝÀÇ ½ÃÇàÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, Áø´Ü¾àÀÇ ÀϰüµÈ »ç¿ëÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÇöÀå °Ë»ç ¹× °íó¸® ½ÇÇè½Ç Ç÷§ÆûÀÇ È®ÀåÀ¸·Î ¹ßº´¿¡ ´ëÇÑ ½Å¼ÓÇÑ ´ëÀÀÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ½Äǰ ¾ÈÀü ¹× °øÁß º¸°Ç °¨½Ã¸¦ À§ÇÑ ±ÔÁ¦ ÃÊÁ¡Àº ÀÇ·á, ȯ°æ ¹× ½Äǰ »ê¾÷ ÀÀ¿ë ºÐ¾ß¿¡¼­ ³ë·Î ¹ÙÀÌ·¯½º Áø´Ü ¾àǰÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(½Å¼Ó °Ë»ç ŰƮ, PCR ŰƮ, ELISA ±â¹Ý ŰƮ), ÃÖÁ¾»ç¿ë(º´¿ø ÃÖÁ¾»ç¿ë, Áø´Ü ½ÇÇè½Ç ÃÖÁ¾»ç¿ë, Ŭ¸®´Ð ÃÖÁ¾»ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°è °íÀ¯ÀÇ SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Norovirus Diagnostics Market to Reach US$106.1 Million by 2030

The global market for Norovirus Diagnostics estimated at US$69.0 Million in the year 2024, is expected to reach US$106.1 Million by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Rapid Test Kits, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$68.3 Million by the end of the analysis period. Growth in the PCR Kits segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$18.1 Million While China is Forecast to Grow at 7.2% CAGR

The Norovirus Diagnostics market in the U.S. is estimated at US$18.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$17.0 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Norovirus Diagnostics Market - Key Trends & Drivers Summarized

Why Is Demand for Norovirus Testing Increasing in Healthcare Settings?

Norovirus is one of the most common causes of viral gastroenteritis worldwide, affecting individuals across all age groups. Due to its high transmissibility, outbreaks often occur in hospitals, long-term care facilities, schools, and cruise ships. The need for timely and accurate diagnosis has increased as healthcare systems aim to reduce the spread of infection and manage outbreaks efficiently. Unlike other gastrointestinal illnesses, norovirus can spread quickly through contaminated surfaces, food, or water, making early identification critical.

Routine diagnostic practices now incorporate norovirus testing, especially for patients presenting with acute diarrhea in institutional settings. Clinicians increasingly require rapid, sensitive tools to differentiate norovirus from bacterial and other viral infections. The growing adoption of diagnostic testing in outpatient care and emergency settings reflects heightened clinical awareness and regulatory emphasis on infection control protocols.

How Are Diagnostic Technologies Evolving to Improve Speed and Accuracy?

Technological advancements are driving the shift from traditional enzyme immunoassays toward molecular diagnostics that offer greater sensitivity and specificity. Real-time PCR-based assays and multiplex panels are now widely used for detecting norovirus genogroups in stool samples. These platforms deliver rapid results, enabling healthcare providers to take timely preventive measures and initiate appropriate care.

Point-of-care testing devices are also emerging for decentralized use in clinics and care facilities, providing faster turnaround without the need for centralized labs. Improvements in assay design, sample preparation, and nucleic acid amplification are supporting reliable detection of low viral loads. Multiplex molecular tests that include norovirus along with other enteric pathogens are increasingly preferred in clinical workflows to streamline diagnosis in gastroenteritis cases.

What Institutional and Public Health Trends Are Expanding Testing Adoption?

Institutions such as hospitals, schools, and elder care centers are investing in routine norovirus screening protocols to reduce the impact of outbreaks. Public health agencies have implemented stricter guidelines for managing acute gastroenteritis in high-risk environments, contributing to more frequent diagnostic testing. Laboratories are adopting automated systems that allow high-throughput norovirus detection during peak seasons or in outbreak scenarios.

Global travel and food service industries also play a role, as foodborne and waterborne transmission drive demand for diagnostic surveillance. In response, food safety laboratories and environmental testing services are incorporating norovirus assays to meet compliance and quality control standards. Surveillance programs tracking genotypic variation and outbreak sources rely heavily on laboratory-confirmed norovirus cases, further integrating diagnostics into broader epidemiological monitoring systems.

Growth in the norovirus diagnostics market is driven by several factors.

Rising incidence of norovirus-related outbreaks in institutional and community settings is pushing demand for rapid and accurate diagnostic tools. Technological improvements in molecular testing, including real-time PCR and multiplex platforms, are enhancing detection speed and reliability. Increasing implementation of infection control protocols in hospitals, long-term care facilities, and schools is encouraging more consistent use of diagnostics. Expansion of point-of-care testing and high-throughput lab platforms is supporting faster outbreak response. Regulatory focus on food safety and public health surveillance is further driving adoption of norovirus diagnostics across healthcare, environmental, and food industry applications.

SCOPE OF STUDY:

The report analyzes the Norovirus Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Rapid Test Kits, PCR Kits, ELISA-based Kits); End-Use (Hospitals End-Use, Diagnostics Labs End-Use, Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â